Omeros (OMER) Equity Average (2011 - 2026)
Omeros recorded quarterly Equity Average of -$92.3 million in Q1 2026, up 45.99% quarter-over-quarter from -$170.9 million in Q4 2025, and up 53.41% year-over-year from -$60.2 million in Q1 2025.
Omeros' Equity Average history runs 16 years deep, the most recent figure standing at -$92.3 million for Q1 2026.
- In Q1 2026, Equity Average rose 53.41% year-over-year to -$92.3 million; the TTM figure through Mar 2026 stood at -$92.3 million (up 53.41% YoY), while the FY2025 annual figure was -$151.9 million, down 46.36% from the prior year.
- Equity Average came in at -$92.3 million for Q1 2026 at Omeros, up from -$170.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $70.3 million in Q1 2023 to a low of -$224.6 million in Q3 2025.
- A 5-year average of -$76.4 million and a median of -$48.2 million in 2024 frame the typical range for Equity Average.
- Across the five-year window, Equity Average surged 645.8% in 2023 and plunged 4350.84% in 2024, its largest moves.
- Omeros' Equity Average stood at $19.7 million in 2022, then sank by 198.9% to -$19.5 million in 2023, then plunged by 764.98% to -$168.4 million in 2024, then declined by 1.46% to -$170.9 million in 2025, then jumped by 45.99% to -$92.3 million in 2026.
- According to Business Quant data, Equity Average over the past three periods registered -$92.3 million, -$170.9 million, and -$224.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -92.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.28 Mn |
| Dec 31, 2025 | -170.85 Mn |
| Sep 30, 2025 | -224.58 Mn |
| Jun 30, 2025 | -221.12 Mn |
| Mar 31, 2025 | -198.08 Mn |
| Dec 31, 2024 | -168.39 Mn |
| Sep 30, 2024 | -139.39 Mn |
| Jun 30, 2024 | -97.96 Mn |
| Mar 31, 2024 | -48.16 Mn |
| Dec 31, 2023 | -19.47 Mn |
| Sep 30, 2023 | 3.28 Mn |
| Jun 30, 2023 | 37.72 Mn |
| Mar 31, 2023 | 70.31 Mn |
| Dec 31, 2022 | 19.69 Mn |
| Sep 30, 2022 | -39.51 Mn |
| Jun 30, 2022 | -18.81 Mn |
| Mar 31, 2022 | 9.43 Mn |
| Dec 31, 2021 | -119.46 Mn |
| Sep 30, 2021 | -254.50 Mn |
| Jun 30, 2021 | -234.13 Mn |
| Mar 31, 2021 | -171.35 Mn |
| Dec 31, 2020 | -104.04 Mn |
| Sep 30, 2020 | -124.30 Mn |
| Jun 30, 2020 | -146.57 Mn |
| Mar 31, 2020 | -120.44 Mn |
| Dec 31, 2019 | -124.47 Mn |
| Sep 30, 2019 | -135.09 Mn |
| Jun 30, 2019 | -125.65 Mn |
| Mar 31, 2019 | -110.59 Mn |
| Dec 31, 2018 | -94.58 Mn |
| Sep 30, 2018 | -72.65 Mn |
| Jun 30, 2018 | -42.76 Mn |
| Mar 31, 2018 | -16.01 Mn |
| Dec 31, 2017 | 3.20 Mn |
| Sep 30, 2017 | -22.82 Mn |
| Jun 30, 2017 | -51.48 Mn |
| Mar 31, 2017 | -42.78 Mn |
| Dec 31, 2016 | -30.11 Mn |
| Sep 30, 2016 | -35.88 Mn |
| Jun 30, 2016 | -44.87 Mn |
| Mar 31, 2016 | -33.49 Mn |
| Dec 31, 2015 | -17.62 Mn |
| Sep 30, 2015 | -536,000.00 |
| Jun 30, 2015 | 14.89 Mn |
| Mar 31, 2015 | -10.40 Mn |
| Dec 31, 2014 | -34.62 Mn |
| Sep 30, 2014 | -18.60 Mn |
| Jun 30, 2014 | -2.70 Mn |
| Mar 31, 2014 | -6.59 Mn |
| Dec 31, 2013 | -21.14 Mn |
| Sep 30, 2013 | -18.07 Mn |
| Jun 30, 2013 | -14.06 Mn |
| Mar 31, 2013 | -11.20 Mn |
| Dec 31, 2012 | -3.68 Mn |
| Sep 30, 2012 | -10.68 Mn |
| Jun 30, 2012 | -16.61 Mn |
| Mar 31, 2012 | -9.12 Mn |
| Dec 31, 2011 | -738,500.00 |
| Sep 30, 2011 | 7.05 Mn |